These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31437778)

  • 1. Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity.
    Hu Z; Li Y; Xie B; Ning W; Xiao Y; Huang Y; Zhao C; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2019 Nov; 182():111605. PubMed ID: 31437778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
    Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
    Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
    Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators.
    Shoda T; Kato M; Harada R; Fujisato T; Okuhira K; Demizu Y; Inoue H; Naito M; Kurihara M
    Bioorg Med Chem; 2015 Jul; 23(13):3091-6. PubMed ID: 26003343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
    Liang JJ; Yu WL; Yang L; Xie BH; Qin KM; Yin YP; Yan JJ; Gong S; Liu TY; Zhou HB; Hong K
    Eur J Med Chem; 2022 Feb; 229():114081. PubMed ID: 34992039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
    Wang L; Sharma A
    ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs).
    Callis R; Rabow A; Tonge M; Bradbury R; Challinor M; Roberts K; Jones K; Walker G
    J Biomol Screen; 2015 Jul; 20(6):748-59. PubMed ID: 25851036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen and Fulvestrant Hybrids Showed Potency as Selective Estrogen Receptor Down-Regulators.
    Shoda T; Kato M; Fujisato T; Demizu Y; Inoue H; Naito M; Kurihara M
    Med Chem; 2017; 13(3):206-213. PubMed ID: 27494098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells.
    Maximov PY; Abderrahman B; Hawsawi YM; Chen Y; Foulds CE; Jain A; Malovannaya A; Fan P; Curpan RF; Han R; Fanning SW; Broom BM; Quintana Rincon DM; Greenland JA; Greene GL; Jordan VC
    Mol Pharmacol; 2020 Jul; 98(1):24-37. PubMed ID: 32362585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship study of estrogen receptor down-regulators with a diphenylmethane skeleton.
    Nanjyo S; Ohgane K; Yoshioka H; Makishima M; Hashimoto Y; Noguchi-Yachide T
    Bioorg Med Chem; 2019 May; 27(10):1952-1961. PubMed ID: 30940565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
    Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
    J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
    Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
    Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
    Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.
    Zhou J; Shen R; Liu J; Deng X; Xin L; Zhou HB; Huang J
    Bioorg Med Chem; 2023 Mar; 82():117235. PubMed ID: 36905762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
    Xin L; Min J; Hu H; Li Y; Du C; Xie B; Cheng Y; Deng X; Deng X; Shen K; Huang J; Chen CC; Guo RT; Dong C; Zhou HB
    Eur J Med Chem; 2023 May; 253():115328. PubMed ID: 37037140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain.
    Sharma A; Toy W; Guillen VS; Sharma N; Min J; Carlson KE; Mayne CG; Lin S; Sabio M; Greene G; Katzenellenbogen BS; Chandarlapaty S; Katzenellenbogen JA
    ACS Chem Biol; 2018 Dec; 13(12):3374-3384. PubMed ID: 30404440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance.
    Ma Y; Preet A; Tomita Y; De Oliveira E; Zhang L; Ueda Y; Clarke R; Brown M; Rosen EM
    Oncotarget; 2015 Dec; 6(38):40388-404. PubMed ID: 26575173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.
    Wittmann BM; Sherk A; McDonnell DP
    Cancer Res; 2007 Oct; 67(19):9549-60. PubMed ID: 17909066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
    Luo G; Tang Z; Lao K; Li X; You Q; Xiang H
    Eur J Med Chem; 2018 Apr; 150():783-795. PubMed ID: 29587221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.